Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Idea to Innovation

University of Toronto

$118,000.00

Platform for high-throughput screening of biomaterials and engineered tissues

FY 2010-11

Summary
Canada's rapidly aging population has increased demand for technologies that will improve productivity and decrease morbidity and mortality. Regenerative Medicine (RM), incorporating biomaterials and tissue engineering, is a promising approach to enable the elderly to lead happy and productive lives while reining in soaring health care costs. However, despite its promise, few tissue engineering systems have been translated successfully from the laboratory to the clinic. This is due in large part to the limitations of the standard pre-clinical development process, which is based on ""best guesses"" rather than systematic investigations. Encouraged by the successes of cell-based assays in the pharmaceutical industry, there is increasing interest in using similar high-throughput screening (HTS) approaches in RM. The platform technology to be developed in this application will address the critical unmet need for enabling technologies that allow systematic screening and design of next-generation tissue engineering products. Unlike any existing technology, the new platform will enable high-throughput characterization of biomaterial mechanical behaviour and screening of cellular responses in three-dimensional, mechanically-active environments, and will be compatible with existing industry standards and infrastructure. These capabilities will enhance discovery and innovation of improved tissue regeneration and drug therapy strategies, particularly for orthopaedic and dental applications. Upon successful completion of the project, we will partner with a Canadian company to further develop and disseminate the platform to the multibillion dollar regenerative medicine, pharmaceutical, and biotechnology markets. Long-term, this technology will yield products that improve the health of Canadians. We will also equip highly qualified personnel with the interdisciplinary tools required to turn ideas into innovations that will solve Canada's most important health care technology challenges and improve our economic competitiveness.
Program
Idea to Innovation
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
NSERC's Awards Data

As published

Application id
396235-2010
Name nom
Simmons, Craig
Department département
Mechanical and Industrial Engineering
Organization id
31
Institution établissement
University of Toronto
Province en
Ontario
Province fr
Ontario
Country en
CANADA
Country fr
CANADA
Fiscal year exercice financier
2010
Competition year année de concours
2010
Award amount
118000
Program id
I2IPJ
Program name en
Idea to Innovation
Program name fr
De l'idée à l'innovation
Group en
Research partnerships programs
Group fr
Programmes de partenariat
Committee code
96
Committee name en
RPP Internal Decision Cttee
Committee name fr
Cté de décision interne - PPR
Area of application code
1102
Area of application group en
Health, education and social services
Area of application group fr
Santé publique, éducation et services sociaux
Area of application en
Biomedical engineering
Area of application fr
Génie biomédical
Research subject code
1901
Research subject group en
Biomedical engineering
Research subject group fr
Génie biomédical
Research subject en
Biomedical technology
Research subject fr
Technologie biomédicale
Partie
1
Nb partie
1
Application title
Platform for high-throughput screening of biomaterials and engineered tissues
Keyword
NSERC
Application summary
Canada's rapidly aging population has increased demand for technologies that will improve productivity and decrease morbidity and mortality. Regenerative Medicine (RM), incorporating biomaterials and tissue engineering, is a promising approach to enable the elderly to lead happy and productive lives while reining in soaring health care costs. However, despite its promise, few tissue engineering systems have been translated successfully from the laboratory to the clinic. This is due in large part to the limitations of the standard pre-clinical development process, which is based on ""best guesses"" rather than systematic investigations. Encouraged by the successes of cell-based assays in the pharmaceutical industry, there is increasing interest in using similar high-throughput screening (HTS) approaches in RM. The platform technology to be developed in this application will address the critical unmet need for enabling technologies that allow systematic screening and design of next-generation tissue engineering products. Unlike any existing technology, the new platform will enable high-throughput characterization of biomaterial mechanical behaviour and screening of cellular responses in three-dimensional, mechanically-active environments, and will be compatible with existing industry standards and infrastructure. These capabilities will enhance discovery and innovation of improved tissue regeneration and drug therapy strategies, particularly for orthopaedic and dental applications. Upon successful completion of the project, we will partner with a Canadian company to further develop and disseminate the platform to the multibillion dollar regenerative medicine, pharmaceutical, and biotechnology markets. Long-term, this technology will yield products that improve the health of Canadians. We will also equip highly qualified personnel with the interdisciplinary tools required to turn ideas into innovations that will solve Canada's most important health care technology challenges and improve our economic competitiveness.